OKYO Pharma Ltd OKYO
About Quantitative Ratings
Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings. Companies with quantitative ratings are not formally covered by a Morningstar analyst, but are statistically matched to analyst-rated companies, allowing our models to calculate a quantitative moat, fair value, and uncertainty rating.
Trading Information
- Previous Close Price
- $1.54
- Day Range
- $1.46–1.60
- 52-Week Range
- $1.44–3.35
- Bid/Ask
- $1.49 / $1.52
- Shares Outstanding
- 52.48M
- Market Cap
- $79.77M
- Volume/Avg
- 55,505 / 71,764
Key Statistics
- Price/Earnings (Normalized)
- —
- Price/Sales
- —
- Dividend Yield (Trailing)
- 0.00%
- Dividend Yield (Forward)
- 0.00%
- Total Yield
- —
Company Profile
OKYO Pharma Ltd is a biopharmaceutical company. The company is developing therapeutics to improve the lives of patients with inflammatory eye diseases and chronic pain. It offers solutions for various diseases such as Dry Eye Disease, Non-infectious Anterior Uveitis, Allergenic Conjunctivitis, Chronic Pain, and Ocular Pain.
- Sector
- Healthcare
- Industry
- Biotechnology
- Stock Style Box
- Small Value
- Total Number of Employees
- 4
- Website
- https://www.okyopharma.com
Valuation
|
Metric
|
OKYO
|
|---|---|
Price/Earnings (Normalized) | — |
Price/Book Value | — |
Price/Sales | — |
Price/Cash Flow | — |
Price/Earnings
No chart available
Financial Strength
|
Metric
|
OKYO
|
|---|---|
Quick Ratio | 0.53 |
Current Ratio | 0.58 |
Interest Coverage | −31.90 |
Quick Ratio
OKYO
Profitability
|
Metric
|
OKYO
|
|---|---|
Return on Assets (Normalized) | −107.49% |
Return on Equity (Normalized) | — |
Return on Invested Capital (Normalized) | — |
Return on Assets
OKYO
Biotechnology Industry Comparables
|
1-Day Chart
|
Name
|
Price
|
Morningstar Rating for Stocks
|
Capital Allocation
|
Economic Moat
|
Market Cap
|
|---|---|---|---|---|---|---|
| Vertex Pharmaceuticals Inc
VRTX
| Ssmtzdb | Rshnff | $113B | |||
| Regeneron Pharmaceuticals Inc
REGN
| Pswmxbwg | Jfrrq | $65B | |||
| argenx SE ADR
ARGX
| Qjgzxvb | Blh | $55B | |||
| Alnylam Pharmaceuticals Inc
ALNY
| Hpxntjwsz | Hzdpkp | $40B | |||
| Royalty Pharma PLC Class A
RPRX
| Bmtqwpck | Tplyp | $25B | |||
| BioNTech SE ADR
BNTX
| Fcywmjxbw | Mpdky | $22B | |||
| Incyte Corp
INCY
| Glqlsgx | Nhzp | $21B | |||
| Moderna Inc
MRNA
| Dsxffpb | Mnhwp | $19B | |||
| Jazz Pharmaceuticals PLC
JAZZ
| Vftshdr | Gtmd | $14B | |||
| BridgeBio Pharma Inc
BBIO
| Jfqjpwf | Ybhg | $13B |
United States